Medicare Coverage for Cancer Treatment: Part B vs Part D, Clinical Trials, and What Advantage Plans Mean

A cancer diagnosis brings immediate questions about coverage. For Medicare beneficiaries, the answers depend partly on how a drug is administered, a detail that determines whether it falls under Part B or Part D, and partly on whether you have Original Medicare or a Medicare Advantage plan, which affects how quickly you can access care. Understanding the coverage landscape before or shortly after diagnosis helps you make informed decisions and avoid coverage surprises during treatment.

Bryce's Take

If a cancer diagnosis is possible or you are at elevated risk, I would encourage you to think carefully about Original Medicare plus Medigap before defaulting to Advantage. The ability to see any oncologist, any cancer center, any specialist in the country without prior authorization or network restrictions becomes very concrete when a diagnosis arrives. A $0 premium looks different when you are trying to get into a major cancer center.

Part B coverage for cancer treatment

Medicare Part B covers physician-administered cancer treatments including chemotherapy delivered by infusion at a physician's office, hospital outpatient department, or infusion center. Radiation therapy, including external beam radiation, brachytherapy, and stereotactic radiosurgery, is covered under Part B. Part B also covers the physician services associated with oncology care, oncologist visits, pathology, imaging like CT scans and PET scans related to cancer staging and monitoring, and surgical procedures. After the Part B deductible, the standard 80/20 cost-sharing applies. Without Medigap or an Advantage plan to cover the 20%, cancer treatment costs under Part B can become very large.

Part D coverage for oral cancer drugs

Cancer drugs taken orally at home are covered under Part D, not Part B. This includes oral chemotherapy agents, targeted therapies, hormonal treatments, and supportive medications taken as pills or capsules. The distinction between Part B and Part D for cancer drugs comes down to route of administration: IV or infusion is Part B, oral or self-administered is Part D. Because oral cancer drugs can cost thousands of dollars per month, their placement in the formulary and their tier level significantly affect out-of-pocket costs. The $2,000 Part D out-of-pocket cap starting in 2025 provides important protection for beneficiaries on expensive oral cancer drugs.

The Part D $2,000 cap and cancer patients

Starting January 1, 2025, Medicare Part D has an annual out-of-pocket cap of $2,000. This is particularly significant for cancer patients on expensive oral therapies. Previously, high-cost oral cancer drugs could generate tens of thousands of dollars in annual cost-sharing. Under the new cap, your Part D out-of-pocket spending on all covered drugs combined cannot exceed $2,000 per year. For patients on specialty-tier oral cancer drugs, this represents a substantial and immediate reduction in financial exposure.

Clinical trial coverage

Medicare covers routine costs associated with participation in approved clinical trials for cancer and other conditions. Routine costs are the items and services that would be covered by Medicare if received outside the trial, standard doctor visits, laboratory tests, imaging, and supportive care. Medicare does not cover the investigational item or service being studied (the experimental drug or device itself), but that cost is typically covered by the clinical trial sponsor. This coverage requires that the trial be approved and that Medicare is not required to pay for the experimental treatment itself.

Facing a cancer diagnosis and trying to understand your Medicare coverage?

Cancer treatment coverage under Medicare is one of the most consequential plan design questions there is. I am glad to help you understand your options and whether your current plan gives you the access you need.

Book a Free Call

Medicare Advantage and cancer care

Medicare Advantage plans must cover cancer treatment to the same extent as Original Medicare, but they add prior authorization requirements that can create delays and denials. Prior authorization for chemotherapy, radiation, and hospital admissions is common under Advantage plans. Some oncologists report significant delays in starting treatment while awaiting prior authorization decisions. National comprehensive cancer center networks, MD Anderson, Mayo Clinic, Memorial Sloan Kettering, may not be in-network for all Advantage plans. Original Medicare with Medigap provides faster access to any Medicare-accepting provider including these specialty centers.

What Medigap means for cancer patients

For cancer patients or those at elevated cancer risk, Medigap Plan G provides the clearest financial protection. It covers the 20% Part B coinsurance on infused chemotherapy, radiation, and all Part B oncology services with no dollar cap. It allows access to any oncologist, cancer center, or hospital that accepts Medicare, including all major academic medical centers. The contrast with Medicare Advantage, where network restrictions and prior authorization requirements can delay or complicate cancer care, is significant enough that many physicians and patient advocates recommend Medigap specifically for patients with serious diagnoses.

Frequently asked questions

Does Medicare cover immunotherapy for cancer?

Yes. Immunotherapy drugs, including PD-1 inhibitors and CAR-T therapies, are covered under Medicare depending on administration route. IV-administered immunotherapy is covered under Part B as physician-administered infusion. Oral immunotherapy agents fall under Part D. CAR-T cell therapy involves complex administration that is covered under Part A inpatient or Part B outpatient depending on the specific clinical context.

Will Medicare cover a second opinion on a cancer diagnosis?

Yes. Medicare Part B covers physician consultations including second opinions for cancer diagnoses and treatment plans. There is no restriction on seeking a second opinion at any Medicare-accepting facility or physician nationwide.

What if my oncologist is not in my Medicare Advantage network?

You would pay out-of-network rates or face no coverage for non-emergency services depending on plan type. For PPO Advantage plans, out-of-network care is covered at higher cost-sharing. For HMO plans, out-of-network care generally requires prior approval or is not covered except in emergencies. If you develop cancer while in an Advantage plan and your oncologist or preferred cancer center is out of network, you may want to evaluate whether switching to Original Medicare plus Medigap during a Special Enrollment Period is possible and appropriate for your situation.

Does Medicare cover genetic testing for cancer risk?

Medicare covers BRCA testing for women with personal or family history of certain cancers. Coverage for other genetic cancer tests depends on clinical circumstances and supporting documentation. Genetic counseling related to cancer risk is covered under Part B. Coverage of newer genomic tumor profiling tests is evolving and may require prior authorization.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.